---
title: "Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290691174.md"
description: "Calidi Biotherapeutics presented new preclinical data on CLD-501, a TROP2-targeting T-cell engager, at the T-Cell Engager Therapeutic Summit. The data supports localized in-tumor expression to limit off-tumor toxicity. Additionally, the company highlighted progress on its RedTail platform, with lead candidate CLD-401 targeting an IND filing by end-2026."
datetime: "2026-06-24T12:00:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290691174.md)
  - [en](https://longbridge.com/en/news/290691174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290691174.md)
generator: "portal-rs"
---

# Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summit

-   Calidi Biotherapeutics presented new preclinical data on June 24, 2026 for CLD-501, a tumor-targeted T-cell engager program aimed at TROP-2. \* Results were already presented at the T-Cell Engager Therapeutic Summit, outlining an approach designed to activate T-cells within solid tumors. \* Data supported localized, in-tumor expression intended to limit off-tumor toxicity risk that has constrained TROP-2 T-cell engager development. \* The update also highlighted RedTail platform progress, with CLD-401 positioned as the lead candidate and an IND filing targeted by end-2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240800PRIMZONEFULLFEED9751622) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)

## Related News & Research

- [Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose](https://longbridge.com/en/news/298445177.md)
- [Opus Genetics posts OPGx-BEST1 Phase 1/2 low-dose cohort presentation update](https://longbridge.com/en/news/298450508.md)
- [MNOV: Upcoming clinical readouts in ALS and metabolic disease drive near-term value inflection](https://longbridge.com/en/news/298726771.md)
- [Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules](https://longbridge.com/en/news/298728074.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**